Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucrictibant for BK-AE-nC1INH
NCT07046806Phase 2Recruiting
- Sponsor
- Institute for Asthma and Allergy
- Start
- Mar 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deucrictibant in hereditary angioedema (HAE), sponsored by Institute for Asthma and Allergy. Started Mar 2025; status: recruiting.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT07046806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07046806.